Skip to main content

Table 1 Number of sites, enrolled subjects and subjects completing the study by country and region

From: Alzheimer’s disease progression by geographical region in a clinical trial setting

Region/country Number of sites Number enrolled Completers, n (%) a
EXPEDITION IDENTITY b
North America 179 832 325 (72) 140 (37)
 United States 154 714 286 (71) 127 (41)
 Canada 25 118 39 (80) 13 (19)
Western Europe/Israel 112 412 163 (77) 71 (36)
 Belgium 4 8 5 (63)
 Denmark 2 5 3 (60)
 Finland 3 6 6 (100)
 France 16 69 23 (92) 9 (20)
 Germany 23 104 42 (76) 14 (29)
 Israel 7 22 8 (36)
 Italy 18 74 42 (74) 1 (6)
 Spain 16 48 15 (63) 12 (50)
 Sweden 12 37 23 (85) 8 (80)
 United Kingdom 11 39 18 (72) 5 (36)
South America /Mexico 50 196 82 (75) 8 (9)
 Argentina 25 88 43 (67) 0
 Brazil 14 67 39 (85) 0
 Chile 7 17 8 (47)
 Mexico 4 24 0
Eastern Europe/Russia 49 195 38 (61) 5 (4)
 Bulgaria 5 18 1 (6)
 Hungary 4 16 1 (6)
 Poland 13 48 24 (67) 3 (25)
 Romania 4 17 0
 Russia 11 45 14 (54) 0
 Serbia 3 8 0
 Turkey 4 23 0
 Ukraine 5 20 0
Japan 46 191 71 (88) 23 (21)
Asia 40 169 59 (84) 0
 China 6 22 0
 India 7 10 0
 Korea 16 85 33 (79) 0
 Taiwan 11 52 26 (93) 0
Australia/South Africa 25 84 32 (84) 18 (39)
 Australia 18 58 32 (84) 10 (50)
 South Africa 7 26 8 (31)
  1. aFor the EXPEDITION program, a completer was defined as a subject who had completed the 80-week double-blind study period. For the IDENTITY program, a completer was defined as a subject who had completed the 76-week initial treatment period; the denominator in this case was the number of subjects who had opportunity to complete 76 weeks of treatment before the study drug was stopped at request of the sponsor, and the study was amended.
  2. bSeveral countries were included only in the IDENTITY program (Belgium, Denmark, Finland, Israel, Chile, Mexico, Bulgaria, Hungary, Romania, Serbia, Turkey, Ukraine, China, India and South Africa).